Navigation Links
SpectraScience Announces Updates
Date:10/28/2008

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego-based medical device company, today provided an update on the status of its business.

Jim Hitchin, SpectraScience's CEO, commented, "We have begun shipping our cancer detection devices to customers in both the United States and Europe. In addition, machines are now in place in leading research facilities throughout the country including the Mayo Clinic, San Diego VA Hospital, Minnesota Gastroenterology, P.A., the University of Southern California and the Boston University VA Hospital to gather the final data necessary to complete a study on the use of our WavSTAT(R) to detect cancer and pre-cancers of the esophagus. Esophageal cancer is deadly and its incidence is growing at a rate six times faster than that of all other solid tumor types. In the beginning phase of this trial there was greater than 90% sensitivity to detection of cancerous and pre-cancerous tissues and, therefore, we expect the follow-up final trial to be successful. The purpose of the final trial is to obtain a statistically significant sample size that will satisfy the FDA in a planned filing. We anticipate making this filing next year and, subject to approval, begin selling product in the United States immediately thereafter.

We now have the CE mark approval for our cancer and pre-cancer detection in the esophagus ahead of schedule in Europe. This means we will be able to start selling this product much earlier than anticipated, accelerating our revenue and cash flow. We have invested considerable effort internationally and receiving the CE mark is an important step in our progress.

A cornerstone of our business model is our focus on leveraging our existing technology to provide higher sensitivity for the screening of several deadly cancers. During 2009, we plan to begin preparing to submit an application for the use of our non-invasive technology to detect lung cancer. Lung cancer is a major illness annually affecting about 215,000 Americans and resulting in 162,000 deaths.

The Company continues its evolution in our recent transition from research and development to revenue generation, and we feel that we have the foundation built for a successful 2009. As the Company moves forward, we plan to focus our energies on sales and marketing initiatives. We believe SpectraScience is on a sound foundation as we continue to grow our business into a major contributor in the battle against cancer."

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval as an optical non-invasive system that has proven to be more effective in detecting cervical cancer precursors than conventional methods available in the market today.

Contacts:

SpectraScience

Jim Hitchin, Chief Executive Officer (858) 847-0200

Investor Relations

Todd M. Pitcher

Hayden Communications, Inc. (858) 518-1387

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. SpectraScience Receives Final European Certification
2. SpectraScience Acquires Luma Imaging Corporation
3. SpectraScience, Inc. Retains Hayden Communications
4. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
5. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
6. SpectraScience Adds Industry Veteran to Executive Team
7. SpectraScience Awarded Patent for Correcting Image Misalignment
8. SpectraScience Delivers Cancer Diagnosis System to Mayo Clinic and UCSD/VA for Detecting Esophageal Dysplasia in Patients
9. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
10. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
11. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... The American Brain Foundation last ... in Neurology Award (PLINA). The couple joins a prestigious list of past PLINA ... Mondale, actor Michael J. Fox and former U.S. Attorney General Janet Reno. , ...
(Date:4/27/2017)... ... April 27, 2017 , ... SyncDog, Inc. , ... MobileIron Live! 2017 in Santa Clara, California. Each year, MobileIron Live! ... to helping organizations maximize the benefits of mobility in their operations securely. ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its kind, ... purer and more potent than the market has seen before. Swissx uses proprietary strains ... as a patented chromatography process for extraction, to produce its CBD oil--maximizing its benefits ...
(Date:4/27/2017)... ... 2017 , ... Plastic Surgery Associates is excited to announce that Heather Furnas, ... upcoming Aesthetic Meeting. Held in San Diego, at the San Diego Convention Center, the ... their expertise to the Premier Global Hot Topics session, speaking on genital rejuvenation. , ...
(Date:4/26/2017)... St. Louis, Missouri (PRWEB) , ... April 26, ... ... optimal cost, quality and clinical outcomes, today released the podcast, “Make Plans ... Act in bringing value-based payment into the physician's office and how physicians and ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Ind. , April 20, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Care Conference at the InterContinental Hotel in ... Zimmer Biomet will present at 11:20 a.m. Eastern Time. ... be accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... 2017   ZappRx, Inc ., a digital health company ... today announced it closed $25 million in Series B funding ... based in Seattle that is part ... The Series B round included participation from SR One ... GV (formerly Google Ventures). As part of the ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
Breaking Medicine Technology: